Download PDF

1. Company Snapshot

1.a. Company Description

Pfizer Inc.discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.


The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands.In addition, the company is involved in the contract manufacturing business.It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers.


The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc.Pfizer Inc.was founded in 1849 and is headquartered in New York, New York.

Show Full description

1.b. Last Insights on PFE

Pfizer's recent performance is driven by several positive factors. The company's Q2 earnings beat estimates, with a 36% EPS beat, driven by aggressive cost-cutting and a strong non-COVID portfolio, led by oncology and rare disease drugs. A direct-to-consumer deal and a three-year tariff reprieve also contributed to the positive momentum. Additionally, a landmark drug-pricing deal with the US government may present further upside potential. The company's dividend is considered safe, with a high yield of 6.28% and a forward PE of 8.87. Institutional investors are also showing strong buying interest.

1.c. Company Highlights

2. Pfizer's 2025 Earnings: A Strong Performance

Pfizer reported a robust financial performance for 2025, with revenues of $62.6 billion and operational revenue growth of 6% when excluding COVID-19 products. The company's adjusted diluted EPS was $3.22, ahead of expectations. In the fourth quarter, revenues were $17.6 billion, with non-COVID product performance growing 9% operationally versus the same period last year. Adjusted gross margin for the quarter was approximately 71%, reflecting a strong product mix and cost management. The company's reported diluted GAAP performance was a loss per share of 29¢, while adjusted diluted earnings per share was $0.66, beating estimates of $0.567.

Publication Date: Feb -04

📋 Highlights

Segment Performance

The company's non-COVID product portfolio performed well, driven by products such as Abrysvo, Eliquis, Prevnar, and the Vyndaqel family. The company's COVID-19 products saw a significant decline, with revenues decreasing by approximately 40% operationally year-over-year. Dave Denton, CFO, noted that the company's refined commercial strategy was effective, driven by these key products.

Pipeline Progress

Pfizer made significant progress in its pipeline, with 40 approvals and critical readouts, and the initiation of 11 pivotal studies. The company's obesity portfolio saw a major advancement with the VSPR three study results, demonstrating robust weight loss with its investigational next-generation injectable GLP-1 receptor agonist, PF-3944. Chris Boshoff, Chief Scientific Officer, highlighted the potential of this platform, stating that the results "provide a compelling validation of our unique proprietary ultra-long-acting peptide platform."

Valuation

Using Pfizer's current valuation metrics, we can assess what's priced in. The company's P/E Ratio is 14.92, and the Dividend Yield is 6.67%. With an ROE of 10.91%, the company is generating strong returns on equity. Analysts estimate next year's revenue growth at -3.3%, which may impact the company's valuation. However, with a robust pipeline and a strong non-COVID product portfolio, Pfizer is well-positioned for long-term growth.

Outlook

Pfizer expects total company full-year 2026 revenues to be in the range of $59.5 billion to $62.5 billion and adjusted diluted earnings per share to be in the range of $2.80 to $3.00 per share. The company is focused on investing in key assets, managing upcoming LOEs, and driving growth through its advancing R&D pipeline and business development initiatives. With a strong financial performance and a promising pipeline, Pfizer is poised for continued success.

3. NewsRoom

Card image cap

Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund

Feb -10

Source: reuters.com

Card image cap

SVB Wealth LLC Reduces Stock Position in Pfizer Inc. $PFE

Feb -10

Source: defenseworld.net

Card image cap

Should You Buy Pfizer's Stock for Its 6.3%-Yielding Dividend?

Feb -09

Source: fool.com

Card image cap

Should You Buy, Sell or Hold Pfizer Stock After a Lukewarm Q4?

Feb -09

Source: zacks.com

Card image cap

Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones

Feb -09

Source: globenewswire.com

Card image cap

Pfizer: 'Hold' As Patent Cliff Looms, Along With Need For Differentiating Factor In Obesity

Feb -09

Source: seekingalpha.com

Card image cap

3 High-Yield Dividend Stocks Perfect For Retirees

Feb -06

Source: 247wallst.com

Card image cap

3 Healthcare Stocks Paying the Highest Dividends of 2026

Feb -06

Source: fool.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (7.85%)

6. Segments

Global Biopharmaceuticals Business (Biopharma)

Expected Growth: 7.9%

Pfizer's Biopharma segment is driven by the increasing demand for innovative medicines and a strong pipeline of oncology and inflammation products, which is expected to contribute significantly to the company's growth.

Pfizer Centreone (pc1)

Expected Growth: 5.2%

None

Pfizer Ignite

Expected Growth: 7.5%

Pfizer Ignite accelerates biomedical innovations, driving growth through strategic investments, partnerships, and talent acquisition, positioning Pfizer Inc. for strong market growth

7. Detailed Products

Comirnaty

COVID-19 vaccine

Ibrance

Cancer treatment

Xeljanz

Rheumatoid arthritis treatment

Viagra

Erectile dysfunction treatment

Chantix

Smoking cessation treatment

Lyrica

Pain management treatment

Prevnar 13

Pneumococcal conjugate vaccine

Xalkori

Cancer treatment

Sutent

Cancer treatment

8. Pfizer Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Pfizer Inc. has a moderate threat of substitutes due to the presence of alternative treatments and generic drugs in the market.

Bargaining Power Of Customers

Pfizer Inc. has a low bargaining power of customers due to the lack of negotiating power of individual customers in the pharmaceutical industry.

Bargaining Power Of Suppliers

Pfizer Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers of raw materials and services.

Threat Of New Entrants

Pfizer Inc. has a low threat of new entrants due to the high barriers to entry in the pharmaceutical industry, including high research and development costs and regulatory hurdles.

Intensity Of Rivalry

Pfizer Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry among competitors.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 44.86%
Debt Cost 3.95%
Equity Weight 55.14%
Equity Cost 6.86%
WACC 5.55%
Leverage 81.35%

11. Quality Control: Pfizer Inc. passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Gilead Sciences

A-Score: 6.8/10

Value: 3.3

Growth: 3.0

Quality: 9.3

Yield: 7.0

Momentum: 9.5

Volatility: 8.3

1-Year Total Return ->

View Full Report
Stock-Card
Pfizer

A-Score: 6.4/10

Value: 5.6

Growth: 2.9

Quality: 6.9

Yield: 9.0

Momentum: 5.5

Volatility: 8.3

1-Year Total Return ->

View Full Report
Stock-Card
Merck

A-Score: 6.2/10

Value: 4.6

Growth: 6.2

Quality: 8.2

Yield: 6.0

Momentum: 4.5

Volatility: 8.0

1-Year Total Return ->

View Full Report
Stock-Card
Bristol-Myers Squibb

A-Score: 5.5/10

Value: 5.0

Growth: 3.9

Quality: 6.5

Yield: 8.0

Momentum: 1.5

Volatility: 8.0

1-Year Total Return ->

View Full Report
Stock-Card
Lilly

A-Score: 5.3/10

Value: 0.0

Growth: 7.1

Quality: 7.5

Yield: 2.0

Momentum: 9.5

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
Biogen

A-Score: 5.3/10

Value: 6.2

Growth: 3.0

Quality: 7.7

Yield: 0.0

Momentum: 7.5

Volatility: 7.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

27.61$

Current Price

27.61$

Potential

-0.00%

Expected Cash-Flows